Cargando…

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma

To analyze whether neoadjuvant chemotherapy (NAC) changes the expression rates of invasive ductal carcinoma (IDC) markers: estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki67, and P53. This was a retrospective study of 112 IDC patients who underw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Jian-Heng, Zhang, Xiang, Song, Jun-Long, Ran, Liang, Luo, Rong, Li, Hong-Yuan, Wang, Yong-Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	5750
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336639/ https://www.ncbi.nlm.nih.gov/pubmed/30633152 http://dx.doi.org/10.1097/MD.0000000000013554

Ejemplares similares

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma: Erratum
Publicado: (2022)

Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population
por: Wang, Jiayu, et al.
Publicado: (2016)

Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis
por: Tao, Miaomiao, et al.
Publicado: (2017)

Comparison of clinicopathological characteristics and prognosis among patients with pure invasive ductal carcinoma, invasive ductal carcinoma coexisted with invasive micropapillary carcinoma, and invasive ductal carcinoma coexisted with ductal carcinoma in situ: A retrospective cohort study
por: Guan, Xin, et al.
Publicado: (2020)

Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab
por: Wang, Xinle, et al.
Publicado: (2019)

Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis
por: Ma, Hong-Fang, et al.
Publicado: (2023)

Application of neoadjuvant chemotherapy in occult breast cancer: Five case reports
por: Yang, Haisong, et al.
Publicado: (2017)

Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer
por: Choi, Jin Hyuk, et al.
Publicado: (2020)

Changes in HER2 status and survival outcomes in patients with non-pathological complete response after neoadjuvant targeted treatment
por: Ren, Xiaofei, et al.
Publicado: (2023)

Mining immune-related genes with prognostic value in the tumor microenvironment of breast invasive ductal carcinoma
por: He, Qiang, et al.
Publicado: (2021)

High expression of MORC2 predicts worse neoadjuvant chemotherapy efficacy in triple negative breast cancer
por: Liao, Xiaohong, et al.
Publicado: (2023)

Prognostic significance of preoperative albumin to fibrinogen ratio associated nomograms in patients with breast invasive ductal carcinoma
por: Zheng, Lihua, et al.
Publicado: (2020)

Comparison of the ductal carcinoma in situ between White Americans and Chinese Americans
por: Kuang, Xin-Wen, et al.
Publicado: (2021)

Management of the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: A single-center study
por: Aksoy, Suleyman Ozkan, et al.
Publicado: (2020)

Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
por: Jiaxin, Chen, et al.
Publicado: (2022)

Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
por: Choi, Ji Soo, et al.
Publicado: (2016)

A single nucleotide polymorphism in codon F31I and V57I of the AURKA gene in invasive ductal breast carcinoma in Middle East
por: Golmohammadi, Rahim, et al.
Publicado: (2017)

Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
por: Puri, Vandana, et al.
Publicado: (2011)

Changes in ischemia-modified albumin in myocardial toxicity induced by anthracycline and docetaxel chemotherapy
por: Luan, Xiao-Dong, et al.
Publicado: (2017)

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67
por: Xu, Junnan, et al.
Publicado: (2018)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

A case report of a patient with ductal carcinoma and a malignant phyllodes tumor in situ in 2 separate breasts
por: Li, Chen, et al.
Publicado: (2023)

HER2-positive pure mucinous breast carcinoma: A case report and literature review
por: Zhao, Xingjuan, et al.
Publicado: (2020)

Identification of potential key genes for HER-2 positive breast cancer based on bioinformatics analysis
por: Lin, Yuxiang, et al.
Publicado: (2020)

Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy
por: Cao, Lu, et al.
Publicado: (2016)

Diagnosis and treatment of advanced HER2-positive breast cancer in young pregnant female: A case report
por: Tang, Tiantian, et al.
Publicado: (2020)

fHER2, PR, ER, Ki-67 and Cytokeratin 5/6 Expression in Benign Feline Mammary Lesions
por: Soares, Maria, et al.
Publicado: (2022)

Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance
por: Hu, Xueyang, et al.
Publicado: (2023)

Impact of Breast Cancer Subtype Defined by Immunohistochemistry Hormone Receptor and HER2 Status on the Incidence of Immediate Postmastectomy Reconstruction
por: Wu, Wei, et al.
Publicado: (2016)

Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer
por: Li, Jingping, et al.
Publicado: (2021)

Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer
por: Chen, Jim-Ray, et al.
Publicado: (2017)

Prognostic nomogram for female patients suffering from non-metastatic Her2 positive breast cancer: A SEER-based study
por: Wu, Jiangwen, et al.
Publicado: (2022)

Concomitant fulvestrant with reirradiation for unresectable locoregional recurrent estrogen receptor positive (ER+) breast cancer: A case report and narrative review
por: Ding, Jingxian, et al.
Publicado: (2020)

Triple mapping for axillary staging after neoadjuvant therapy: Axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy
por: Tasdoven, Ilhan, et al.
Publicado: (2022)

Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: Case report
por: García, Francisco José Valdivia, et al.
Publicado: (2020)

Change of HER2 status during disease recurrence predicts good prognosis for primary squamous cell carcinoma of the breast: A case report
por: Cao, Yong, et al.
Publicado: (2019)

Risk assessment model for invasive breast cancer in Hong Kong women
por: Wang, Feng, et al.
Publicado: (2016)

Adjuvant therapy for HER2 positive pT1a-b pN0 breast cancer: A single center cohort study
por: Yang, Xuan, et al.
Publicado: (2022)

Clinical study on Yanghe decoction in improving neo-adjuvant chemotherapy efficacy and immune function of breast cancer patients
por: Zhang, Xinyue, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_435ah6r9ofu49r95tl1eek13ha